<DOC>
	<DOCNO>NCT01277406</DOCNO>
	<brief_summary>The purpose study determine Maximum Tolerated Dose ( MTD ) 4SC-201 ( Resminostat ) combination FOLFIRI whether 4SC-201 ( Resminostat ) effective safe combination FOLFIRI versus FOLFIRI alone treatment advanced colorectal carcinoma .</brief_summary>
	<brief_title>4SC-201 ( Resminostat ) Advanced Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Phase I : Histologically cytologically confirm advanced stage colorectal carcinoma Documented progression precedent treatment accord RECIST criterion ECOG performance status 0 2 Live expectancy 12 week Patients must previously receive treatment 5FU alone combination antitumor medication Patients foreseen chemotherapy FOLFIRI second line treatment Exclusion Criteria Phase I : Patients receive previous treatment HDAC inhibitor Anticipation need major surgical procedure radiation therapy ( RT ) study Therapy agent know prolong QT interval , certain antibiotic ( e.g . erythromycin , clarithromycin ) , antidepressant ( e.g . doxepin , amitryptiline ) neuroleptic ( e.g . haloperidol , clozapine ) Patients homozygous UGT1A1 characterize presence additional TA repeat TATA sequence UGT1A1 promoter ( ( TA ) 7TAA ) ) . For patient show good tolerability irinotecan precedent treatment line accord investigator 's judgement , availability UGT1A1 result mandatory study inclusion Therapy strong CYP3A4 inhibitor ( e.g . ketoconazole ) inductor ( e.g . carbamazepine , phenytoin , St. John 's Wort ) Severe internal disease : insufficiently treat uncontrolled arterial hypertension , hemoptoe , New York Heart Association ( NYHA ) grade II great congestive heart failure , symptomatic coronary heart disease , myocardial infarction ( ≤ 12 month prior inclusion ) , serious cardiac arrhythmia require medication , peripheral arterial occlusive disease stage II great , uncontrolled severe disease Patients confirm QTcF &gt; 480 m , history additional risk factor Torsades de Pointes Major surgery within last 4 week Inclusion Criteria Phase II : Histologically cytologically confirm advanced stage colorectal carcinoma Documented progression precedent treatment accord RECIST criterion Kras mutation ( contraindicate EGFR inhibitor therapy , result local pathology accept inclusion ECOG performance status 0 2 Live expectancy 12 week Patients must previously receive treatment 5FU alone combination antitumor medication Patients foreseen chemotherapy FOLFIRI second line treatment Exclusion Criteria Phase II arm : Patients receive previous treatment HDAC inhibitor Anticipation need major surgical procedure radiation therapy ( RT ) study Therapy agent know prolong QT interval , certain antibiotic ( e.g . erythromycin , clarithromycin ) , antidepressant ( e.g . doxepin , amitryptiline ) neuroleptic ( e.g . haloperidol , clozapine ) Patients homozygous UGT1A1 characterize presence additional TA repeat TATA sequence UGT1A1 promoter ( ( TA ) 7TAA ) ) . Therapy strong CYP3A4 inhibitor ( e.g . ketoconazole ) inductor ( e.g . carbamazepine , phenytoin , St. John 's Wort ) Severe internal disease : insufficiently treat uncontrolled arterial hypertension , hemoptoe , New York Heart Association ( NYHA ) grade II great congestive heart failure , symptomatic coronary heart disease , myocardial infarction ( ≤ 12 month prior inclusion ) , serious cardiac arrhythmia require medication , peripheral arterial occlusive disease stage II great , uncontrolled severe disease Patients confirm QTcF &gt; 480 m , history additional risk factor Torsades de Pointes Major surgery within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Resminostat</keyword>
	<keyword>HDAC</keyword>
	<keyword>4SC-201</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
</DOC>